Primary squamous cell carcinoma of the breast: A case report and review of the literature

Primary squamous cell carcinoma (PSCC) of the breast, as a rare metaplastic breast cancer, currently has limited clinical data on its biological behavior, treatment and prognosis. At present, the optimal treatment of this tumor is still controversial. We reported a case of a 56-year-old woman with a...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 1033084
Main Authors Wu, Yaping, Chen, Zhiying, Li, Wei, Wang, Fengguang, Zhang, Yongchun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 06.01.2023
Subjects
breast metaplastic carcinoma
breast squamous cell carcinoma (BSqCC)
case report
Oncology
recurrence
treatment
breast metaplastic carcinoma
recurrence
treatment
case report
breast squamous cell carcinoma (BSqCC)
Online AccessGet full text

Cover

More Information
Summary:Primary squamous cell carcinoma (PSCC) of the breast, as a rare metaplastic breast cancer, currently has limited clinical data on its biological behavior, treatment and prognosis. At present, the optimal treatment of this tumor is still controversial. We reported a case of a 56-year-old woman with a mass on the right breast. She underwent a modified radical mastectomy and lymph node biopsy, which revealed that the tumor was a metaplastic squamous cell carcinoma with axillary lymph node metastasis, followed by traditional adjuvant chemotherapy and radiotherapy. The patient re-examined by PET/CT after two years in May 2017 and found a recurrence in the right chest wall, so resection of the recurring lesion was resected, then she was given postoperative adjuvant radiotherapy and chemotherapy. In August 2019, the patient re-examined by PET/CT, and there were pulmonary and mediastinal lymph node metastases. After 4 cycles of albumin paclitaxel plus cisplatin chemotherapy combined with nivolumab immunotherapy, the patient achieved complete response (CR), and then switched to nivolumab immune maintenance therapy. So far, no obvious metastasis has been seen. We believe that surgical treatment is necessary for PSCC of the breast;paclitaxel and cisplatin chemotherapy regimens and adjuvant radiotherapy are effective, but it may be resistant to radiotherapy; and immunotherapy may prolong the survival of patients with PSCC of the breast.
Bibliography:Reviewed by: Xinyu Zheng, The First Affiliated Hospital of China Medical University, China; Bilgin Kadri Aribas, Bülent Ecevit University, Turkey
This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology
Edited by: Ianik Plante, KBRwyle, United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.1033084